Comparative Pharmacology
Head-to-head clinical analysis: BENDAMUSTINE HYDROCHLORIDE versus CYTOXAN LYOPHILIZED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDAMUSTINE HYDROCHLORIDE versus CYTOXAN LYOPHILIZED.
BENDAMUSTINE HYDROCHLORIDE vs CYTOXAN (LYOPHILIZED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bendamustine is a bifunctional mechlorethamine derivative that alkylates and crosslinks DNA, leading to DNA damage, inhibition of DNA synthesis, and apoptosis. It also activates p53-dependent DNA repair stress pathways and induces mitotic catastrophe.
Cyclophosphamide is an alkylating agent that cross-links DNA, inhibiting DNA replication and transcription. It also has immunosuppressive effects by suppressing B and T lymphocyte function.
120 mg/m² intravenously over 60 minutes on days 1 and 2 of each 21-day cycle, for up to 6 cycles (in combination with rituximab for indolent B-cell non-Hodgkin lymphoma). Other regimens exist; refer to specific protocol.
500-1000 mg/m² IV every 2-4 weeks, or 60-120 mg/m² IV daily for 2-3 days, or 500-750 mg/m² IV every 3 weeks. Oral: 50-200 mg daily as continuous therapy.
None Documented
None Documented
Terminal half-life: ~40 minutes (unchanged drug); active metabolites (M3, M4): 3-4 hours. Clinical context: short half-life of parent drug necessitates infusion protocol; metabolites accumulate and correlate with myelosuppression.
Cyclophosphamide: 4-8 hours (dose-dependent, prolonged in hepatic impairment). Active metabolites (e.g., phosphoramide mustard): 6-12 hours.
Renal: ~50% (mainly as metabolites, <5% unchanged). Biliary/fecal: ~40% as metabolites. Approximately 90% of dose eliminated within 72 hours.
Renal: 30-60% of unchanged drug and metabolites (primarily phosphoramide mustard and acrolein). Biliary/fecal: minor (<10%).
Category D/X
Category C
Alkylating Agent
Alkylating Agent